Engineering scFvs for in vivo
CAR-T Success

Accelerate IND timelines with scFvs engineered from
proprietary, commercialization-ready sequences.

Request Quote

As in vivo CAR-T accelerates into the next wave of cell therapy innovation, CGT teams need high-specificity, high-affinity, low-immunogenicity scFvs that can deliver genetic payloads precisely-without the delays or IP uncertainty of traditional discovery.

Powered by the SMabTM single-B-cell platform, Yurogen provides flow-validated, high-performance antibody sequences that can be rapidly engineered into targeted scFvs built for in vivo CAR-T success. Fast to screen, clean on IP, and ready for translation-so your program moves forward with confidence.

Why CGT Companies Choose Yurogen?
scFv Engineering Workflow

Your in vivo CAR-T scFv, Delivered with Speed and Reliability

Partial List of Available in vivo CAR-T Targets

Ready-to-Use Antibody Sequences for scFv Engineering

CategoryKey TargetsTimeline
B-cell–AssociatedCD19, CD20, CD22 scFv engineering 1 week.
Antibody expression 2 weeks.
Solid TumorTROP-2, Glypican 3 (GPC3)
T-cell LeukemiaCD3, CD5, CD7, CD8a

Note: This table shows selected targets. Additional targets and clone options are available upon request.

Ready to Accelerate Your in vivo CAR-T Program?

Advance with targeted, high-performance scFvs designed for speed, clarity,
and commercialization confidence.

Start a Project

ISO 9001:2015 certified QMS